Clinical Trials · NCT02500979
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 34
- Start date
- Aug 2015
- Locations
- 3 sites, United States
- Primary endpoint
- Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM)